Antimicrobial activity of quinupristin/dalfopristin, a new injectable streptogramin with a wide Gram-positive spectrum

International Journal of Antimicrobial Agents

Volumn 13, Issue 1, 1999, Pages 21-28

  Speciale, A ^a   La Ferla, K ^a   Caccamo, F ^a   Nicoletti, G ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; CEFIXIME; CEFTRIAXONE; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; IMIPENEM; MEROPENEM; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; SPARFLOXACIN; SPIRAMYCIN; STREPTOGRAMIN; TEICOPLANIN; VANCOMYCIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE COCCI; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; VIRGINIAMYCIN;

EID: 0032850806     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(99)00092-8     Document Type: Article

References (22)

1. Johnson A.P., Uttley A.H.C., Woodford N., George R.C. Resistance to vancomycin and teicoplanin: an emerging clinical problem. Clin. Microbiol. Rev. 3:1990;280-291.
2. Goldstein F.W., Coutrot A., Sieffer A., Acar J.F. Percentage and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci. Antimicrob. Agents. Chemother. 34:1990;899-900.
3. Spera RV, Faber BF. Multiply resistant Enterococcus faecium. The nosocomial pathogen of the 1990's. J Am Med Assoc 1992: 2563-2564.
4. Speller D.C.E., Lynn W.A., Rogers T.R. Glycopeptide resistance in Gram-positive bacteria. Clin. Microbiol. Infect. 1:1995;54-59.
5. Pankuch G.A., Jacobs M.R., Appelbaum P.C. Study of comparative pneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin and vancomycin by using time-kill methodology. Antimicrob. Agents. Chemother. 38:1994;2065-2072.
6. Aumercier M., Bouhallab S., Capmen M.L., Le Goffic F. RP 59500: a proposed mechanism for its bactericidal activity. J. Antimicrob. Chemother, Suppl. A. 30:1992;9-14.
7. Brumfitt W., Hamilton-Miller J.M.T., Shaah S. In vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic against Gram-positive bacteria. J. Antimicrob. Chemother, Suppl. A. 30:1992;29-37.
8. Finch R.G. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use. Drugs, Suppl. 1. 51:1996;31-37.
9. Low D.E., Nadler H.L. A review of in vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and resistant Staphylococcus aureus. J. Antimicrob. Chemother, Suppl. A. 39:1997;53-58.
10. Williams J.D., Maskell J.P., Whiley A.C., Sefton A.M. Comparative in vitro activity of quinupristin/dalfopristin against Enterococcus spp. J. Antimicrob. Chemother, Suppl. A. 39:1997;41-46.
11. National Committee for Clinical laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 4th ed: Approved Standard M7-A4. NCCLS. Villanova PA, 1997.
12. Craig WA, Gudmundsson S. The post-antibiotic effect. In: Lorian, Williams, Wilkins, editors. Antibiotics in Laboratory Medicine, 5th ed. Baltimore, 1991. p. 403-431.
13. Inone M., Okamoto R., Okubo T., Inone K., Mitsuhashi S. Comparative in vitro activity of RP 59500 against clinical bacterial isolates. J. Antimicrob. Chemother, Suppl. A. 30:1992;45-51.
14. Verbist L., Verhaegen J. Comparative in vitro activity of RP 59500. J. Antimicrob. Chemother, Suppl. A. 30:1992;39-44.
15. Linden P, Pasculle AW, Riddler S, Kusne S, Silverman A, Dean J. Quinupristin/dalfopristin (RP 59500) for the treatment of the serious infections due to high level of vancomycin-resistant Enterococcus faecium. In: Program and Abstract of the 34th Interscience Conference on Antimicrobiotic Agents and Chemotherapy, 1994, Abstract M66, p. 126.
16. Hill R.L.R., Smith C.T., Seyed-Akhavani M., Casewell M.W. Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium. J. Antimicrob. Chemother, Suppl. A. 23:1997;28-39.
17. Vedel G., Lernez M., Lemann F., Hraoni E., Ratovahery D. Prevalence of S. aureus and coagulase-negative staphilococci with decreased sensitivity to glycopeptides as assessed by determination of MICs. Eur. J. Clin. Microbiol. Infect. Dis. 9:1990;820-822.
18. Hoban D.J., Weshnoweski B., Paltatniak L., Zanel C.G., Davidson R.J. In vitro activity of RP 59500 against clinical bacterial isolates. J. Antimicrob. Chemother, Suppl. A. 30:1992;59-65.
19. Fass R. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin against staphylococci, streptococci and enterococci. Antimicrob. Agents. Chemother. 35:1991;553-559.
20. Caron, F, Gold, HS, Wennersten, CB, Moellering, RC, Eliopoulos, GM. Role of growth phase and erythromycin susceptibility on bactericidal effect of RP 59500 (quinupristin/dalfopristin) against vancomycin-resistant Enterococcus faecium strains. In: Program and Abstracts of the Third International Conference on Macrolides, Azalides and Streptogramins, Lisbon, Abstract 6.17, 1996, p. 60.
21. Lena Kang S., Rybak M.J. In vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus. JAC, Suppl. A. 39:1997;33-39.
22. Cin N.X., Neu H.C. Post-antibiotic effect of the new streptogramin RP 59500. Eur. J. Clin. Microb. Infect. Dis. 11:1992;642-645.